Kelowna, British Columbia — August 27, 2025 — Leads & Copy — Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) will participate in the 27th Annual H.C. Wainwright Global Investment Conference, from Sept. 8-10, 2025. CEO Richard Christopher will present and hold investor meetings. The presentation will be available remotely after 7:00 AM EST on Sept. 5.
Investors interested in scheduling a meeting with the
Lexaria management team should contact their H.C. Wainwright
representative or send an email to: meetings@hcwco.com
DehydraTECH™ is Lexaria’s patented drug delivery formulation and processing platform technology which improves the way
a wide variety of drugs enter the bloodstream, always through oral
delivery. DehydraTECH has repeatedly evidenced the ability to
increase bio-absorption, reduce side-effects, and deliver some drugs
more effectively across the blood brain barrier. Lexaria operates a
licensed in-house research laboratory and holds a robust intellectual
property portfolio with 50 patents granted and additional patents
pending worldwide.
George Jurcic – Head of Investor Relations can be reached at ir@lexariabioscience.com or Phone: 250-765-6424, ext 202.
Source: Lexaria Bioscience Corp.
